Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hansoh Pharmaceutical Group Company Limited

翰 森 製 藥 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"

The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that

"bortezomib for injection" developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪 森藥業集團有限公司), a subsidiary of the Company, was tentatively approved by the United States

Food and Drug Administration ("FDA").

Bortezomib for injection is indicated for the treatment of Multiple Myeloma and Mantle cell lymphoma.

By Order of the Board

Hansoh Pharmaceutical Group Company Limited

Zhong Huijuan

Chairlady

Hong Kong, May 10, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.